Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States

NCT00997386 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Neoplasms
Multiple Myeloma
Anemia, Aplastic
Hemoglobinuria, Paroxysmal
Myelofibrosis

Interventions

DRUG: busulfan, and melphalan, and alemtuzumab

Sponsor

University of Arizona